NIH

Resiniferatoxin offers targeted, non-opioid pain relief in cancer patients

June 3, 2025

A first-in-human clinical trial demonstrated that resiniferatoxin (RTX), derived from the Euphorbia resinifera plant, is a safe and effective analgesic for patients with intractable cancer pain. A single injection into lumbar cerebrospinal fluid lowered worst-pain intensity by 38% and opioid use by 57%, allowing patients to regain function.

RTX specifically targets TRPV1-expressing nerve fibers, blocking pain signals without affecting other sensory modalities. This precision distinguishes it from conventional treatments that broadly disrupt nerve function. Beyond cancer pain, RTX may hold promise for neuroma pain, trigeminal neuralgia, post-surgical pain, and chronic oral inflammation.

Source:

(2025, May 29). NIH. NIH scientists pioneer promising treatment for intractable cancer pain. https://www.nih.gov/news-events/news-releases/nih-scientists-pioneer-promising-treatment-intractable-cancer-pain